Asset Details
Do you wish to reserve the book?
Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets
Do you wish to request the book?
Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets
2019
Overview
Rationale Tumor infiltrating lymphocytes are widely associated with positive outcomes, yet carry key indicators of a systemic failed immune response against unresolved cancer. Cancer immunotherapies can reverse their tolerance phenotypes, while preserving tumor-reactivity and neoantigen-specificity shared with circulating immune cells. Objectives We performed comprehensive transcriptomic analyses to identify gene signatures common to circulating and tumor infiltrating lymphocytes in the context of clear cell renal cell carcinoma. Modulated genes also associated with disease outcome were validated in other cancer types. Findings Using bioinformatics, we identified practical diagnostic markers and actionable targets of the failed immune response. On circulating lymphocytes, three genes, LEF1, FASLG, and MMP9, could efficiently stratify patients from healthy control donors. From their associations with resistance to cancer immunotherapies and microbial infections, we uncovered not only pan-cancer, but pan-pathology failed immune response profiles. A prominent lymphocytic matrix metallopeptidase cell migration pathway, is central to a panoply of diseases and tumor immunogenicity, correlates with multi-cancer recurrence, and identifies a feasible, non-invasive approach to pan-pathology diagnoses. Conclusions The non-invasive differently expressed genes we have identified warrant future investigation towards the development of their potential in precision diagnostics and precision pan-disease immunotherapeutics.
Publisher
American Society for Clinical Investigation
Subject
/ Cancer
/ Carcinoma, Renal Cell - genetics
/ Carcinoma, Renal Cell - immunology
/ Carcinoma, Renal Cell - pathology
/ Carcinoma, Renal Cell - therapy
/ Clear cell-type renal cell carcinoma
/ Female
/ Gene Expression Regulation, Neoplastic - immunology
/ Genes
/ Humans
/ Kidney Neoplasms - immunology
/ Kidney Neoplasms - pathology
/ Lymphocytes, Tumor-Infiltrating - immunology
/ Lymphocytes, Tumor-Infiltrating - pathology
/ Male
/ Neoplasm Proteins - genetics
/ Neoplasm Proteins - immunology
/ Patients
/ Tumor Microenvironment - immunology
/ Tumor-infiltrating lymphocytes
/ Tumors
